Physician profile
Ameet Kumar
NPI 1184005654
$1,203.03
in general payments reported to CMS, 2019-2025
13 companies · $62.67 in 2025
The $62.67 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $156 · 2021: $142 · 2022: $185 · 2023: $84.88 · 2024: $249 · 2025: $62.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $242.03 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $221.85 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $139.60 | 2023-2024 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals Lp | $135.05 | 2019-2025 | Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $82.94 | 2020-2021 | |
| Abbott Laboratories | $79.61 | 2019 | |
| Abbvie INC. | $72.24 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $52.79 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.45 | 2021-2022 | |
| Gilead Sciences, INC. | $51.32 | 2021-2022 | |
| Biomerieux INC | $38.13 | 2019 | |
| Vifor Pharma, INC. | $21.81 | 2019 | |
| Pfizer INC. | $13.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ameet Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.